Pharmaceutical compositions for the treatment of CNS and other discorders

A compound of the formula

• 8
• wherein n=1-2;
• m=1-2;
• o=1-2;
• X=O, S, or NR1;
• Y=O, S, or NR1;
• R1 is H, a straight chain or branched (C1-C8)alkyl, C(═O)OR6, CH2R6, C(═O)NR6R7, C(═O)R6, or SO2R6;
• Q is a straight chain or branched (C1-C8)alkyl, a straight chain or branched (C2-C8)alkenyl, a straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11) aryl or 5-12 membered heteroaryl;
• wherein Q is optionally substituted with one to six substituents R2 independently selected from H, F, Cl, Br, I, nitro, cyano, CF3, —NR3R4, —NR3C(═O)R4, —NR3C(═O)NR4R5, —NR3S(═O)2R4, —NR3S(═O)2NR4R5, —OR3, —OC(═O)R3, —OC(═O)R3 —OC(═O)NR3R4, —OC(═O)SR3, —C(═O)OR3, —C(═O)R3, —C(═O)NR3R4, —SR3, —S(═O)R3, —S(═O)2R3, —S(═O)2NR3R4, and R3;
• each R3, R4, and R5 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11) aryl and 5-12 membered heteroaryl;
• wherein R3, R4, and R5, when not =H, are each independently optionally substituted with from one to six substituents, independently selected from F, Cl, Br, I, nitro, cyano, CF3, —NR6R7 —NR6C(═O)R7, —NR6C(═O)NR7R8, —NR6S(═O)2R7, —NR6S(═O)2NR7R8, —OR6, —OC(═O)R6, —OC(═O)OR6, —OC(═O)NR6R7, —OC(═O)SR6, —C(═O)OR6, —C(═O)R6, —C(═O)NR6R7, —SR6, —S(═O)R6, —S(═O)2R6, —S(═O)2NR6R7, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11) aryl, 5-12 membered heteroaryl, and R6;
• or, when R3 and R4 are as in NR3R4, they may instead optionally be connected to form with the nitrogen of NR3R4 to which they are attached a heterocycloalkyl moiety of from three to seven ring members, said heterocycloalkyl moiety optionally comprising one or two further heteroatoms independently selected from NR5, O, S;
• each R6, R7, and R8 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11) aryl and (5-12 membered heteroaryl;
• wherein R6, R7, and R8 are each independently optionally substituted with from one to six substituents, independently selected from F, Cl, Br, I, nitro, cyano, CF3, —NR9R10, —NR9C(═O)R10, —NR9C(═O)NR10R11, —R9S(═O)2R10, —NR9S(═O)2NR10R11, —OR9, —OC(═O)R9, —OC(═O)OR9, —OC(═O)NR9R10, —OC(═O)SR9, —C(═O)OR9, —C(═O)R9, —C(═O)NR6R7, —SR6, —S(═O)R6, —S(═O)2R6, —S(═O)2NR6R7, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, (5-11 membered) heterobicycloalkenyl, (C6-C11) aryl, 5-12 membered heteroaryl, and R9;
• each R9, R10, and R11 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, (5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11) aryl and 5-12 membered heteroaryl;
• with the proviso that when n is one, o is one, m is two, X is oxygen and Y is oxygen or NR1, then Q can not be unsubstituted phenyl or phenyl substituted only with one or more substituents selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, (C1-C6) alkyl, (C1-C6) alkoxy, the group —OCH2O— attached to both the meta and para positions of the phenyl ring, the group —CH2CH2CH2CH2— attached to both the meta and para positions of the phenyl ring, and phenoxy or phenyl wherein said phenyl and the phenyl moiety of said phenoxy can optionally be substituted with one or more substituents selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, (C1-C6) alkyl, and (C1-C6) alkoxy;
• or an enantiomeric, diastereomeric, and tautomeric isomer of such compound, or a pharmaceutically acceptable salt of such compound or isomer.